Literature DB >> 24528283

Challenges for opioid receptor nomenclature: IUPHAR Review 9.

Brian M Cox1, Macdonald J Christie, Lakshmi Devi, Lawrence Toll, John R Traynor.   

Abstract

UNLABELLED: Recent developments in the study of the structure and function of opioid receptors raise significant challenges for the definition of individual receptor types and the development of a nomenclature that precisely describes isoforms that may subserve different functions in vivo. Presentations at the 2013 meeting of the International Narcotics Research Conference in Cairns, Australia, considered some of the new discoveries that are now unravelling the complexities of opioid receptor signalling. Variable processing of opioid receptor messenger RNAs may lead to the presence of several isoforms of the μ receptor. Each opioid receptor type can function either as a monomer or as part of a homo- or heterodimer or higher multimer. Additionally, recent evidence points to the existence of agonist bias in the signal transduction pathways activated through μ receptors, and to the presence of regulatory allosteric sites on the receptors. This brief review summarizes the recent discoveries that raise challenges for receptor definition and the characterization of signal transduction pathways activated by specific receptor forms. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
© 2014 The British Pharmacological Society.

Mesh:

Substances:

Year:  2014        PMID: 24528283      PMCID: PMC4292949          DOI: 10.1111/bph.12612

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

1.  Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.

Authors:  J Gelernter; H Kranzler; J Cubells
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

2.  C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization.

Authors:  T Koch; S Schulz; M Pfeiffer; M Klutzny; H Schröder; E Kahl; V Höllt
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

3.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

Review 4.  G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.

Authors:  Graeme Milligan
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

6.  Genetic-epigenetic interaction modulates μ-opioid receptor regulation.

Authors:  Bruno G Oertel; Alexandra Doehring; Bianca Roskam; Mattias Kettner; Nadja Hackmann; Nerea Ferreirós; Peter H Schmidt; Jörn Lötsch
Journal:  Hum Mol Genet       Date:  2012-08-08       Impact factor: 6.150

7.  Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones.

Authors:  Miquel Martin; Audrey Matifas; Rafael Maldonado; Brigitte L Kieffer
Journal:  Eur J Neurosci       Date:  2003-02       Impact factor: 3.386

8.  Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.

Authors:  R B Rothman; C P France; V Bykov; B R De Costa; A E Jacobson; J H Woods; K C Rice
Journal:  Eur J Pharmacol       Date:  1989-08-29       Impact factor: 4.432

9.  Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4.

Authors:  Hiroshi Fukagawa; Tomohiro Koyama; Masahiro Kakuyama; Kazuhiko Fukuda
Journal:  J Anesth       Date:  2012-08-25       Impact factor: 2.078

10.  μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.

Authors:  Didier Cussac; Isabelle Rauly-Lestienne; Peter Heusler; Frédéric Finana; Claudie Cathala; Sophie Bernois; Luc De Vries
Journal:  Cell Signal       Date:  2012-04-25       Impact factor: 4.315

View more
  45 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Themed section.

Authors:  M J Christie; M Connor; J R Traynor
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

3.  Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 4.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  In vivo opioid receptor heteromerization: where do we stand?

Authors:  D Massotte
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 6.  Central N/OFQ-NOP Receptor System in Pain Modulation.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  Adv Pharmacol       Date:  2015-12-17

7.  Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.

Authors:  Barbora Melkes; Lucie Hejnova; Jiri Novotny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-06       Impact factor: 3.000

Review 8.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

Review 9.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

10.  Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

Authors:  A Gupta; W Fujita; I Gomes; E Bobeck; L A Devi
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.